Levobupivacaine hydrochlorideLevobupivacaine hydrochloride
MedChemExpress (MCE)
HY-B0653A
27262-48-2
(S)-(-)-Bupivacaine monohydrochloride
99.98%
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture)
Room temperature in continental US
may vary elsewhere.
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
Levobupivacaine (0-4 mM
24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells[2]. Levobupivacaine (2 mM
24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities
induces the levels of Fe2+, iron, and lipid ROS[2]. Levobupivacaine (2 mM
24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe2+ and iron[2].
Levobupivacaine (40 μmol/kg
IP
once daily for 25 days) significantly inhibits SGC7901 cell growth, and enhances the lipid ROS accumulation[2]. Levobupivacaine (5 or 36 mg/kg
IP
single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage
reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage[3].
Sodium channels, Ferroptosis[1] Cellular Effect Cell Line Type Value Description References
| | | |
| | | | | |
[1]. Sanford M, et al. Levobupivacaine: a review of its use in regional anaesthesia and pain management. Drugs. 2010 Apr 16
70(6):761-91. [Content Brief]
[2]. Mao SH, et al. Levobupivacaine Induces Ferroptosis by miR-489-3p/SLC7A11 Signaling in Gastric Cancer. Front Pharmacol. 2021 Jun 9
12:681338. [Content Brief]
[3]. Marganella C, et al. Comparative effects of levobupivacaine and racemic bupivacaine on excitotoxic neuronal death in culture and N-methyl-D-aspartate-induced seizures in mice. Eur J Pharmacol. 2005 Aug 22
518(2-3):111-5. [Content Brief]